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ABSTRACT 
BACKGROUND:  Certain herbal medicines have been reported to be effective in the 
treatment of psychiatric onditions, and combination treatment with drugs and herbal 
medicines has been reported to be useful in enhancing treatment efficacy and reducing 
recovery time and adverse vents (AEs). 
OBJECT IVE:  The purpose of this study was to investigate he e~}ectiveness and tolera- 
bility of warm-supplementing kidney yang (~'SKY) added to risperidone in improving 
cognitive impairment and negative symptoms (ie, cognitive function) in patients with 
schizophrenia. 
METHODS:  This 8-we&, multicenter, randomized, ouble-blind, placebo-controlled 
clinical trial was conducted in patients who met the clinical classification for schizophre- 
nia according to the Diagnostic and Statistical Manua! of Mental Disorders, Fou#th Edition, 
Text Revision. Patients were recruited from 3 centers (including inpatient and outpatient 
clinics) and were evenly randomized to receive E'¢'SKY or placebo added to risperidone 
for 8 weeks. Primary assessments were conducted at weeks 2, 4, and 8. A clinical response 
was defined as a >50% reduction score (from baseline) on the Positive and Negative 
Syndrome Scale (PANSD, a >30% reduction score (from baseline) on the Scale for the 
Assessment ofNegative Symptoms (SANS), or a >50% reduction score (from baseline) on 
the Hamilton Rating Scale for Depression (HAM-D-17). Cognitive function was assessed 
using the Wisconsin Card Sorting ~lbst (WCST) at baseline and end point. Extrapyramidal 
AEs were assessed weekly using the Abnormal Involuntary Movement Scale (AIMS) and 
the Rating Scale for Extrapyramidal Side Effects (RSESE). AEs were assessed by patient 
interviews conducted at each clinic visit and also by the Treatment Emergent Symptoms 
Scale (TESS) scores. 
RESULTS:  One-hundred twenty patients (62 males, 58 females; mean [SD] age, 
34.4 [9.4] years; range, 18 45 years; baseline mean [SD] PANSS score, 88.7 [12.3]) were 
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included in this study. Risperidone- and WSKY-treated patients had statistically sig- 
nificant improvements atend point in the number of completed categories (P 0.019), 
perseverative r sponses (P 0.041), perseverative errors (P 0.040), and total errors 
(P 0.049) on the WCST compared with placebo. The improvements in the PANS& 
SANS, and HAM-D-17 scores were not significantly different between the 2 groups at 
week 8 for observed case and last-observation-carried-forward (LOCF) analyses. The 
response rates (LOCF) for the PANSS scores in the ~TSKY and placebo groups were 
55.0% and 35.0%, respectively (P 0.028), while the SANS scores were 63.3% and 
45.0% (P 0.044) and the HAM-D-17 were 35.0% and 45.0% (P 0.264). There were 
no significant between-group differences in scores on the AIMS, RSESE, or TESS. 
CONet .US|ONS:  The results of this study suggest hat ~SKY added to risperi- 
done significantly improved cognitive function in these patients, as measured by the 
number of completed categories, perseverative responses, perseverative errors, and total 
errors on the WCST compared with placebo. The response rates in the WSKY group 
for the PANSS and SANS scores were significandy higher compared with placebo. All 
treatments were generally well tolerated. (Cuff Ther Res C/iv Exp. 2008;69:104 117) O 
2008 Excerpta Medica Inc. 
KEY WORDS:  traditional Chinese medicine, schizophrenia, cognitive function, wa, m- 
supplementing kidney yang, ~SKY,  negative symptoms. 
INTRODUCTION 
Cognitive deficits have been found to remain stable in ambulatory patients with schizo- 
phrenia, regardless of changes in clinical state. 1The neurocognitive p rformance of pa- 
tients with schizophrenia is closely correlated with several key outcome domains (eg, the 
development of new social skills, the ability to function independently in the com- 
munity). Neurocognitive p rformance is viewed as a limiting factor to treatment success 
and rehabilitation. 2,3 It has been viewed as a key factor in schizophrenia pathology. 
In clinical studies, 4 5 cognitive symptoms (eg, impaired performance on the backward 
masking, span of apprehension, Wisconsin Card Sorting tasks) were found to be sig- 
nificantly related to negative symptoms (ie, diminution or loss of normal functions) but 
no clear association was found between positive symptoms (ie, excess or distortion of 
normal functions) and neurocognitive deficits. Hawkins et al ~ reported that schizo- 
phrenic patients with negative symptoms had significantly reduced (P < 0.01) cognitive 
function compared with patients without negative symptoms. Both syndromes are con- 
sidered to be more resistant o psychopharmacologic interventions and to affect the 
psychosocial outcome to a greater degree than positive symptoms] Along with cogni- 
tive performance, negative symptoms are among the top informative bng-term prog- 
nostic outcome factors to consider in patients with schizophrenia. 8 Additionally, patients 
with a preponderance of negative symptoms might exhibit a generalized cognitive defi- 
cit (eg, memory, verbal fluency). However, cognitive improvement has been reported to 
ameliorate some of the difficult-to-treat negative symptoms. 9 
In comparison with conventional ntipsychotics, atypical antipsychotic drugs t~.ve 
some advantages: they have greater efficacy against both positive and negative symptoms, l° 
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and they reduce the incidence of extrapyramidal symptoms (EPS) and tardive dyskine- 
sia. ll Studies 12,13 have reported that atypical ant!psychotic drugs have greater efficacy 
against neurocognitive deficits, termed veurocogvitive adva,etage, and have reported 
improvements in cognition after switching patients from conventional to atypical anti- 
psychotic drugs. 
Some herbal medicines have been reported to be effbctive in the treatment of psy- 
chiatric conditions, and combination treatment with drugs and herbal medicines has 
been reported to be useful in enhancing efficacy and in reducing both recovery time 
and adverse vents (AEs). 14 Traditional Chinese medicine (TCM) has been found to be 
significantly more effective than ant!psychotic drugs in treating anxiety and depression, 
while at the same time, preventing psychomotor inhibition. 15 
According to TCM, schizophrenia s a syndrome caused by a yin-yang imbalance 
characterized by spleen and stomach weakness and inadequate kidney yin. > Herbal 
preparations such as warm-supplementing kidney yang (V4TSKY) or strong kidney yin 
is believed to improve deficits associated with schizophrenia. ~XrSKY comes in capsule 
form, and each capsule contains 13 traditional Chinese herbs: Radix Acovitf Latera!is 
Preparata (RALP), Morivda of/~cfvafis How, Herba epimedii, Curcu!igo orchioides Gaertv, 
Civvamomum cassia Pfes4 Rhizoma zhegibefis, Codovopsis pilosu!a, Raagix astfagali, Radix 
Rehmavviae Pfaepafam, Pfastfum Testudivis, Peficafpium Citfi Reticulatae, Amomum vilfosum 
Louf, and GfTcTffhiza ufafevsis Fisch37 Aconitine is the main active ingredient in RALP, 
which is believed to have the ability to excite or release acetylcholine in brain tissue 
and hypothalamic corticotrophin-releasing hormone neurons, isStudies 19,2° have investi- 
gated the antidepressant effect of Moffvda ofj~civalis oligosaccharides or its main active 
ingredient. Hefba epimedii has been reported to increase hypothalamic monoamine 
neurotransmitter concentrations in aging male rats and improve learning and memory 
in aging rats and mice. 21 It can also inhibit the activities of acetylcholine in both brain 
tissue and whole blood in mice. el Epimedium polysaccharides might improve the 
body's regulation of neuroimmunologic effects and could delay senilitye2; they may also 
improve cognition and negative symptoms in schizophrenic patients. 
The purpose of this study was to investigate the effectiveness and tolerability of 
\VSKY added to risperidone in improving cognitive impairment and negative symp- 
toms fie, cognitive function) in patients with schizophrenia. 
PAT IENTS AND METHODS 
PAT IENTS 
Male and female patients aged 18 to 45 years with a clinical diagnosis of schizophre- 
nia according to the Diagreostfc arid Statistic~! kdareual of ~ieJeta! Disorders, Fourth Editior4 
Text Revisiov 23 were eligible for the study. Additional inclusion criteria were as follows: 
a score >4 on the Clinical Global Impression Severity Scale 24 (scale grading ranges from 
1~ with 1 not ill at all and 7 very ill), predominance of negative symptoms as 
indicated by the Positive and Negative Syndrome Scale (PANSS) 25 (scale grading ranges 
from 1~ with 1 absent, 2 slight, 3 mild, 4 moderate, 5 slight severe, 6 
severe, and 7 very severe) (indicated by a negative subscale score >21 and >1 point 
higher than the positive subscale score), a score <7 on the Hamilton Rating Scale for 
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Depression (HAM-D-17) 26 a 17-item questionnaire measuring the severity of depres- 
sion (scale grading ranges f}om 0 4 with 0 absent, 1 mild or trivial, 2 or 3 mod- 
erate, and 4 severe), and a score <5 on the Rating Scale for Extrapyramidal Side Effects 
(RSESE) 27 (scale grading ranges from 0 4 with 0 normal, 1 mikL 2 moderate, 
3 severe, and 4 very severe). Exclusion criteria included substance abuse, dependence, 
or intoxication; suicidal tendencies; medical history of head trauma, epileps B thyroid 
disease, or meningoencephalitis; electrocardiography (ECG) abnormalities; laboratory 
findings (blood and urine) >20%, outside of the refbrence range; pregnancy or lactation; 
treatment with clozapine within 4 weeks of enrollment; and initiation of psychotherapy 
within 1 month of commencement of he study. 
STUDY DES IGN AND PROCEDURES 
This 8-week, multicenter, andomized, ouble-blind, placebo-controlled clinical trial 
was conducted between January 2004 and December 2006 at 3 cenmrs (including inpa- 
tient and outpatient clinics): Renmin Hospital, k~Tuhan University, Wuhan, China; Youfu 
Hospital of Wuhan, Wuhan, China; and Third Renmin Hospital, Jingmen, China. 
All raters underwent interrater reliability training using training modules. Intraclass 
correlation coefficients were >0.85 for all objective scales. 
This study was approved by the hospitals' institutional review boards, and all pa- 
tients gave written informed consent. If the patients were not able to give consent, fami- 
ly members provided consent. The study protocols conformed to the principles of tile 
Declaration of Helsinki. 2s All examinations and assessments were free of charge, and com- 
pensation fur transportation and telephone fees/charges during the study period was 
provided. 
The KXTSKY capsules and placebo capsules were distributed by the Pharmacy Depart- 
ment of Third Renmin Hospital in accordance with the standards of the Chinese Food 
and Drug Supervision Bureau. The study drug was a 0.3 g 13-herb combination capsule. 
The placebo capsules contained 0.3 g of starch and were identical in appearance to the 
study drug. 
The investigators were blinded to the randomization schedule during the study. 
However, individual treatment codes, indicating the treatment group for each patient, 
were available to the investigators. The treatment codes were disclosed only in the case 
of a medical emergency (ie, when appropriate management of the patient required rug 
treatment disclosure). 
During the screening period, the patients underwent physical examination, ECG, 
hematologic and urine testing, blood chemistry screening (alanine aminotransferase, 
aspartate aminotransferase, alkaline phosphatase, total protein, albumin, globulin, 
direct bilirubin, total bilirubin, urea, creatinine, uric acid, glucose, total cholesterol, 
and triglyceride), and scale assessment. The screenings were carried out by normal 
procedure. After screening, patients were randomized to receive ~XrSKY or placebo 
added to risperidone using SAS software version 8.2 (SAS Institute Inc., Cary, North 
Carolina). The x~TSKY and placebo capsules were randomly nmnbered from 1 to 140. 
Patients received a number according to the time they entered the trial (ie, patient 1 
received rug 1; patient 2 received rug 2). The patients were assigned to a clinical 
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investigator and scheduled to see the same clinical investigator for consultation and 
assessments (PANSS, Scale for the Assessment of Negative Symptoms [SANS], 29 [scale 
grading ranges from 1~ with 1 absent, 2 slight, 3 mild, 4 moderate, 5 slight 
severe, 6 severe, and 7 very severe] arid the HAM-D-17) to evaluate symptoms and 
cognitive functions during psychiatric linical visits at the end of weeks 2, 4, and 8. 
A response rate was defined as a >50% reduction score from baseline on the PANSS, 
a >30% reduction score (from baseline) on the SANS, or a >50% reduction score (from 
baseline) on the HAM-D-17. 
At each visit, patients were questioned whether they had experienced any health- 
related issues since the previous visit and were also assessed using the Treatment 
Emergent Symptoms Scale (TESS), 3° (scale grading ranges from 0 4 with 0 absent, 
1 slight, 2 mild, 3 moderate, and 4 severe). The patients were instructed to 
report AEs at a W time during the study. Compliance was determined by medication 
count conducted by an investigator (Z.C., X.W., or H.W.). Noncompliance was deter- 
mined if drug administration rate was <75%. At the final visit, physical examination, 
ECG, hematologic and urine testing, and blood chemistry screening were repeated. 
Additionally, a final assessment was completed at the end of week 8 or at the end point 
(ie, if the patient did not complete the study). 
Patients who had been receiving nondepot antipsychotic treatment underwent a 2- to 
7-day washout period before randomization. Because of the perceived ef}bcts of psycho- 
therapy, initiation of psychotherapy was prohibited uring the study. 
TR~'ATMERT 
~TSKY 0.9 g TID (morning, noon, and evening) or placebo was administered for 
8 weeks. Risperidone was administered as~bllows: 1 mg QN from day 1 to day 4; 1 mg 
BID (noon and evening) from day 5 to day 9; and from day 10 to the end point, the 
risperidone dosage (<8 mg/d) for each patient was adjusted according to the clinical 
judgment of the research psychiatrists. Anticholinergic medication (biperiden hydro- 
chloride <8 mg/d) was administered if EPS were present at study inclusion or had 
developed uring the course of treatment. Concomitant lorazepam (<4 rag) and zopi- 
clone (<15 mg) were allowed to counteract agitation and sleep problems; these drugs 
had to be discontinued >24 hours prior to neurocognitive t sting to reduce threats to 
validity. Antidepressants, mood stabilizers, psychostimulants, and antipsychotic drugs 
other than the study drugs were not allowed during the study. 
STUDY ASSESSMENTS 
Cognitive Function 
The Wisconsin Card Sorting Test (WCST), 31,32 a measure of cognitive function 
(including executive function, abstraction, and working memory) was used to assess the 
ability to generate hypotheses, establish response sets, and fluently shift sets. The test 
includes 4 stimulus cards that differ in 3 characteristics 33 (color [yellow, green, red, blue]; 
shape [triangle, star, cross, circle]; and number [1 4]) and 2 identical sets of 64 response 
cards. Performance was automatically scored by computer at baseline and week 8. The 
test automatically terminated after the patient completed 6 categories or when no more 
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response cards remained. WCST indexes used in the subsequent cak-ulations were the 
number of completed categories, perseverative responses, perseverative errors, total errors, 
and unique errors. 
Effectiveness a**d 7blerability 
The patients were assessed at baseline and weeks 2, 4, and 8. The primary effec- 
tiveness measures were the scores on the PANSS and SANS. Secondary effectiveness 
measures included the scores on the Social Disability Screening Schedule (SDSS) 34-  
a 10-item scale--(scale grading ranges from 0~ with 0 absent, 1 moderate, and 2 
sever<), HAM-D-17, and positive and general psychopathology PANSS subscales. 
Tolerability was measured by vital signs, weight, ECG, and laboratory findings as 
well as by the assessments using the TESS, Abnormal Involuntary Movement Scale 
(AIMS), and RSESE scales. 
Extrapyramidal AEs were assessed weekly using the AIMS 35 designed to measure 
medicine-induced involuntary movements ( cale grading ranges from 0 4 with 0 none, 
1 minimal, 2 mild, 3 moderate, and 4 severe) and the RSESE. AEs were assessed 
by patient interviews conducted at each clinic visit and also by the TESS scores. 
STAT IST ICAL  ANALYSES 
The primary analyses were perfbrmed on an intent-to-treat basis and included 
all patients who were randomly assigned to treatment and received study medica- 
tion. All end point analyses were conducted using the last-observation-carried-forward 
(LOCF) methodology (ie, the last available visit was used as the end point). Within-group 
changes from baseline to end point (LOCF) were analyzed using the Wilcoxon signed 
rank test. Between-group comparisons of change from baseline were analyzed by analysis 
of covariance, using investigation site, baseline value, and age, which were used as covari- 
ares in the model. Analyses of the primary efficacy variables (PANSS and SANS) were 
performed using visit wise (observed cases [OCsJ) and LOCF data set. A ){2 test was used 
to compare the proportion of positive treatment responses on the PANSS and SANS 
between the 2 groups. The Fisher exact test or the Z 2 test was used to compare AEs 
as appropriate. All statistical tests were 2-tailed, with a significance l vel ofP < 0.05. SPSS 
version 12.0 for Windows (SPSS Inc., Chicago, Illinois) was used for the statistical analy- 
ses. A power analysis was not performed. 
RESULTS 
PAT IENT CHARACTERIST ICS  
Of the 140 patients who were screened, :120 patients (62 males, 58 ~bmales; mean 
[SD] age, 34.4 [9.4] years; age range, 18 45 years; baseline mean [SD] PANSS scores, 
88.7 [12.3]) were included in the study, and 116 (96.7%) completed the 8-week study. 
A total of 4 patients did not complete the entire study: 2 patients in the ~XrSKY group 
(because of abnormal bleeding time, and withdrawn informed consent [1 each]); and 
2 in the placebo group (because of abnormal hepatic function, and withdrawn informed 
consent [1 each]). All patients were adequately compliant (ie, >75% of study drug 
administration). 
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No significant differences were observed in the 2 groups in terms of age, sex, educa- 
tion level, age of onset and duration of illness, or baseline scores on the WCST, PANSS, 
SDSS, HAM-D-17, AIMS, and RSESE (TaMe I). 
The mean dose of risperidone at the last observation was significantly lower in the 
placebo group compared with the WSKY group (3.45 vs 3.80 rag/d; P 0.022). No 
treatment difference was detected in the concomitant use of lorazepam and zopiclone 
between the 2 groups (~SKY 50.2% [31/60], placebo 60.2% [37/60]). 
COGNIT IVE  FUNCTION 
Significant within-group improvement over time in WCST scores was observed for all 
parameters (number of completed categories, nmnber of perseverative responses, number of 
perseverative errors, total number of errors, and number of unique errors) in the WSKY 
group and in the number of completed categories, nmnber of perseverative responses, and 
total number of errors in the placebo group from baseline m the end point (all, P < 0.01) 
(Table II). 
The xX/CST scores were similar in the 2 groups at baseline. The WSKY group signifi- 
cantly improved compared with the placebo group at end point in the number of com- 
pleted categories (P 0.019), perseverative r sponses (P 0.041), perseverative errors 
(P 0.040), and total errors (P 0.049) (Table liD. 
EFFECT IVENESS ANALYSES 
PANSS and SANS scores improved significantly from baseline to end point in both 
the WSKY and placebo groups (all, P < 0.001) (Figure 1); however, there were no 
significant between-group differences in the PANSS or SANS scores. Improvements 
in the PANSS and SANS scores were not significantly different between the 2 groups 
at week 8 in the OC or at end point (LOCF) (F 3.328, P 0.071 and F 0.444, P 
0.516, respectively) (Figure 1). 
For the PANSS and SANS scores, the response rates in the WSKY group were 
significantly higher compared with those in the placebo group for both the LOCF and 
the completers or at the end point (week 8) analyses (Figure 2). The response rates 
(LOCF) for the PANSS scores in the WSKY and placebo groups were 55.0% and 
35.0/%, respectively (P 0.028), while the SANS scores were 63.3% and 45.0% (P 
0.044) and the HAM-D-17 scores were 35.0% and 45.0% (P 0.264). For study 
completers, the response rates of the WSKY and placebo groups for the PANSS scores 
were 56.9% and 36.2%, respectively (P 0.026), while the SANS scores were 63.8% 
and 44.8% (P 0.040). 
The reductions in the SDSS scores and the HAM-D-17 scores from baseline to end 
point (LOCF) were significantly higher in the ~vVSKY group compared with the placebo 
group (F 4.177, P 0.044 and F 5.911, P 0.017, respectively). 
TOLERABIL ITY  ANALYSES 
WSKY or placebo added to risperidone were both well tolerated. Treatment- 
emergent AEs were reported in a similar number of patients in the WSKY and placebo 
groups (32 [53.3%] vs 34 [56.6%], respectively). AEs noted in >3% of the patients in 
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Table I. Baseline demographic and clinical character ist ics  of the study patients (N = 
120) .  Unless otherwise noted, data are mean (SD). There were no significant 
between-group differences. 
WSKY Group Placebo Group 
Characteristic (n = 60) (n = 60) P* 
Age, y 35.8 (9.2) 33.0 (9.6) 0.089 
Sex, no. (%) 0.715 
Male 32 (53.3) 30 (50.0) 
Female 28 (46.7) 30 (50.0) 
Education, y 10.6 (2.5)  11.0 (3.2) 0.464 
Illness, y 
Age of onset 22.6 (5.7) 21.0 (6.2) 0.154 
Duration 13.0 (9.0) :1_0.6 (9.0) 0.203 
WCST scores at baseline 
No. of completed categories 2.1 (2.0) 1.8 (2.0) 0.368 
Total no. of errors 63.8 (26.8) 68.9 (28.8) 0.317 
No. of perseverative responses 36.6 (27.2) 42.7 (37.1) 0.311 
No. ot perseverative errors 30.3 (20.2) 33.2 (27.2) 0.509 
No. of unique errors 34.0 (23.7) 34.5 (28.6) 0.917 
PANSS scores at baseline 
Total 88.7 (:1_2.3) 88.4 (13.:[) 0.903 
Negative subscale 27.1 (5.0) 27.5 (5.3) 0.669 
Positive subscale 18.5 (4.7) :1_7.6 (5.1) 0.374 
General psychopathology 43Ah (7.2) 43.2 (8.2) 0.934 
SDSS score at baseline 13.2 (5.7) 13.6 (4.4) 0.694 
HAM-D-:I_7 score at baseline 5.6 (3.3) 5.3 (4.6) 0.697 
AIMS score at baseline 2.8 (2.4) 3.2 (2.8) 0.345 
RSESE score at baseline 0.2 (0.9) 0.2 (0.9) 0.928 
WSKY = warm-supplementing kidney yang; WCST = Wisconsin Card Sorting Test; PANSS = Positive 
and Negative Syndrome Scale; SDSS = Social Disability Screening Schedule; HAM-D-17 = Hamilton 
Rating Scale for Depression; AIMS = Abnormal Involuntary Movement Scale; RSESE = Rating Scale for 
Extrapyramidal Side Effects. 
*Based on the Z 2 test, independent t test, or analysis of covariance. 
either group are illustrated in Table IV. No significant between-group differences were 
observed in regard to AE incidence. No serious or intolerable AEs were noted. 
No significant between-group differences were noted in changes in vital signs or 
laboratory findings, inchding ECGs. The changes in scores from baseline to end point 
on the AIMS and RSESE were not significantly dif}erent between the groups (F 
1.021, P 0.314 and F 2.524, P 0.115, respectively). No treatment diff':fence was 
detected in the adjunctive use of anticholinergic agents between the 2 groups (~VSKY 
63.3%,, placebo 80.0%). 
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Table II. Within-group comparison of the results of the Wisconsin Card Sorting Test from 
baseline to end point in the warm-supplementing kidney yang (WSKY) group 
and the placebo group (N = 120),* Data are given as mean (SD), 
WSKY Group Placebo Group 
(n = 60) (n = 60) 






2.1 (2.0) 3.4 (1.5) t 1.8 (2.0) 2.2 (1.6)t 
36.6 (27.2) 54.5 (16.4) 1 42.7 (37.1) 47.9 (14.5)t 
30.3 (20.2) 20.7 (10.1)t 33.2 (27.2) 32.9 (18,8) 
63.8 (26.8) 40.1 (18.0)t 68.9 (28.8) 55.0 (24.7)t 
34.0 (23.7) 25.4 (13.6)t 34.5 (28.6) 33.3 (16.1) 
*Last-observation-carried-forward nalysis. 
t p < 0.01 versus baseline. 
DISCUSSION 
To our knowledge, this is the first study to assess the effectiveness and tolerability of 
"~TSKY added to risperidone in improving cognitive functions in patients with schizo- 
phrenia. A search of the literature using the Cochrane Schizophrenia Group Register, 
Traditional Chinese Medical Literature Analysis and Retrieval Database, Chinese 
Biomedical Database, China National Knowledge Int?astructure Database, and the 
Complementary Medicine Database with key terms traditional Chinese medicine, schizo- 
Table III, Between-group comparison of the results of the Wisconsin Card Sorting Test 
(baseline and adjusted mean changes [AMC]) in the warm-supplementing kidney 
yang (WSKY) and placebo groups (N = 120).* Data are mean (SD). 
WSKY Group Placebo Group Analysis of 
(n = 60) (n = 60) Covariance 
Parameter Baseline AMC Baseline AMC F P 
Completed 
categories 2.1 (2.0) -1.4 (2.1) 1.8 (2.0) -0 .5  (2.1) 5.635 0.019 
Pe rseve rative 
responses 36,6 (27.2) -16.8 (31.4) 42.7 (37.1) -3 .9  (35.4) 4,276 0,041 
Pe rseve rative 
errors 30.3 (20.2) 10,6 (19.0) 33.2 (27.2) 1,3 (28.4) 4,330 0.040 
Total errors 63.8 (26.8) 25.5 (25,1) 68.9 (28,8) 16.0 (26.8) 3.961 0.049 
Unique errors 34,0 (23.7) 9.7 (20.6) 34.5 (28.6) 2.2 (24,0) 3,194 0.077 
*Last-observation-carried-forward analysis of data adjusted for investigation site, baseline value, and age. 
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Figure 1. Changes in (A) Positive and Negative Syndrome Scale (PANSS) and (B) Scale for the 
Assessment of Negative Symptoms (SANS) scores in the warm-supplementing 
kidney yang (WSKY) and placebo groups from baseline to end point, *P < 
0.001. 
phrenia, cog,eitive fu~ectio~e, cognition, warm-supplemeeltivg kideley avg, WSKY, and teegative 
symptoms did not find any studies examining the effects of'WSKY on cognitive impair- 
ment and negative symptoms in patients with schizophrenia. 
Our study found that at end point (LOCF), significant improvements were 
found in the \VCST scores in the number of completed categories, perseverative 
responses, perseverative errors, and total errors in the \VSKY group compared 
with the placebo group. The response rates for both LOCF and study completers 
on the PANSS and SANS were significantly higher in the ~ 'SKY  group compared 
with the placebo group. However, the improvements in the PANSS and SANS 
scores were not significantly different between the 2 groups in the OC or at end 
point (LOCF). 
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Figure 2. Response rates on the Positive and Negative Syndrome Scale (PANSS) 
and Scale for the Assessment of Negative Symptoms (SANS) in the warm- 
supplementing kidney yang (WSKY) and placebo groups using data for last- 
observation-carried-forward (LOCF) and completers, *P < 0,05. 
TreatmenFemergent AEs were reported in a comparable number of patients in the 
2 groups. No significant differences in the AEs noted in >5% of the patients were found 
between the groups, and no serious or intolerable AEs were noted in either group. The 
changes in scores from baseline to end point on the AIMS and RSESE were similar in 
the 2 groups. No treamlent differences were found in the a.djuncdve use of andcholin- 
ergic ~.gents. 
Table IV. Treatment-emergent adverse events occurring in _>5% of study participants 
treated with placebo or warm-supplementing kidney yang (WSKY) (N = 120). 
Data are no (%). 
Adverse Event WSKY (n = 60) Placebo (n = 60) P* 
Tremor 14 (23.3) 12 (20.0) 0.551 
Insomnia 10 (16.7) 6 (10.0) 0.720 
Akathisia 8 (13,3) 12 (20.0) 0,127 
Somnolence 8 (13.3) 10 (16,7) 0.192 
Headache 8 (13.3) 7 (11.7) 0,398 
Weight gain 8 (13.3) 7 (11.7) 0,398 
Constipation 7 (11.7) 5 (8.3) 0,423 
Dizziness 4 (6,7) 2 (3.3) 0,059 
Lassitude 3 (5.0) 5 (8.3) 0,268 
Nausea 3 (5,0) 5 (8.3) 0,268 
*Based on the Z 2 tes t  or Fisher exact test, as appropriate. 
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Larger, controlled studies for longer durations are needed to evaluate the true effec- 
tiveness of VJSKY in the treatment of schizophrenia. 
LIMITATIONS 
Because of limited literature, we might have tolerated the pharmacologic a tions of 
some compositions ofWSKY. In addition, the small sample size and the short duration 
of this study should also be considered limitations. 
CONCLUSIONS 
The results of this study suggest that ~SKY added to risperidone significantly improved 
the number of completed categories, perseverative responses, perseverative errors, and total 
errors on the ~VCST compared with placebo added to risperidone in these patients. The 
response rates in the ~SKY group for the PANSS and SANS scores were significantly 
higher than those in the placebo group. All treatments were generally well tolerated. 
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